Aytu BioScience (NASDAQ:AYTU) has extended its distribution right to commercialize the clinically validated COVID-19 IgG/IgM Rapid Test.
The test has been licensed from L.B. Resources,
Limited (a Hong Kong Corporation). The COVID-19 IgG/IgM Rapid Test
delivers clinical results between 2 and 10 minutes at the point-of-care.
This amendment expands Aytu’s commercial rights to
distribute and commercialize the COVID-19 test in North America,
including U.S., Canada and Mexico.
This point-of-care test has been validated in a 113 patient clinical trial and is CE marked.
Shares are up 21% premarket.
https://seekingalpha.com/news/3553306-aytu-bio-expands-distribution-rights-for-covidminus-19-test-shares-up-21-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.